Ostalo

TAPENTADOL THERAPY IN CHRONIC PAIN MANAGEMENT: OUR EXPERIENCE

SANJA BERIĆ LEROTIĆ ; Klinička bolnica Sveti Duh, Klinika za anesteziologiju, reanimatologiju i intenzivno liječenje, Zagreb, Sveučilište Josipa Jurja Strossmayera u Osijeku, Medicinski fakultet, Osijek, Hrvatska
IVAN ŠKLEBAR ; Klinička bolnica Sveti Duh, Klinika za anesteziologiju, reanimatologiju i intenzivno liječenje, Zagreb, Sveučilište Josipa Jurja Strossmayera u Osijeku, Medicinski fakultet, Osijek, Hrvatsko katoličko sveučilište, Zagreb i Visoko učilište Bjelovar, Bjelov
MAJA KARAMAN ILIĆ ; Klinička bolnica Sveti Duh, Klinika za anesteziologiju, reanimatologiju i intenzivno liječenje, Zagreb, Sveučilište Josipa Jurja Strossmayera u Osijeku, Medicinski fakultet, Osijek, Hrvatska
IDA KOŽUL ; Klinička bolnica Sveti Duh, Klinika za anesteziologiju, reanimatologiju i intenzivno liječenje, Zagreb, Hrvatska
MARIN MLIČEVIĆ ; Klinička bolnica Sveti Duh, Klinika za anesteziologiju, reanimatologiju i intenzivno liječenje, Zagreb, Hrvatska

Sažetak

Tapentadol is a novel analgesic registered in slow-release form for medium-intensity and intense chronic pain, which targets both the nociceptive and neuropathic component of the pain signal. It utilizes two synergistic mechanisms: MOR – mu opioid receptor agonism and NRI – norepinephrine reuptake inhibition. The goal of this study was to compare the effectiveness of pain management and tolerability of tapentadol in our clinical experience with existing reports from abroad. The study included 92 patients from our pain management clinic who were prescribed slow-release tapentadol in doses of at least 50 mg
twice daily. We tracked the effectiveness of pain management recorded using the visual analog scale, as well as the appearance and type of adverse effects. Further directions for dose adjustment or discontinuation of therapy were also recorded. In our experience, 66% of patients reported a satisfactory analgesic effect. The adverse effect rate was 43%; 54% of patients discontinued tapentadol therapy, i.e. 37% due to adverse effects, 15% because of inadequate pain management, and 2% because of a negative attitude of their primary care physician. Our study confi rmed the effi cacy of pain management with tapentadol. The total adverse effect rate was comparable to reports found in the literature and was lower than with classical opioid therapy. A relatively high therapy discontinuation rate was noted primarily due to adverse effects.

Ključne riječi

tapentadol; chronic pain; analgesia; drug effectiveness; adverse effects

Hrčak ID:

224645

URI

https://hrcak.srce.hr/224645

Datum izdavanja:

14.7.2019.

Podaci na drugim jezicima: hrvatski

Posjeta: 3.929 *